{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:11:51Z","timestamp":1763035911791,"version":"build-2065373602"},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2004,8,18]],"date-time":"2004-08-18T00:00:00Z","timestamp":1092787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The results of randomized clinical trials have suggested that after receiving radiotherapy and\/or chemotherapy, patients with primary breast carcinoma have an increased risk of developing leukemia. In the current study, the authors set out to assess the reported association between breast carcinoma treatment and leukemia risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>A registry of all patients with breast carcinoma who were treated at a community\u2010based institution since 1989 (updated annually for recurrence and\/or vital status) was linked to the National Cancer Institute Surveillance, Epidemiology, and End Results database to confirm complete ascertainment of leukemia cases occurring within this registry population. Incidence rates were calculated for women who were treated for primary Stage 0\u2013III breast carcinoma and had a follow\u2010up duration of \u2265 24 months (<jats:italic>n<\/jats:italic> = 2866). Patients who did not undergo surgery (<jats:italic>n<\/jats:italic> = 5), patients for whom chemotherapy records were incomplete or who received nonstandard chemotherapy regimens (<jats:italic>n<\/jats:italic> = 69), patients who underwent stem cell transplantation (<jats:italic>n<\/jats:italic> = 83), and patients who were lost to follow\u2010up or who had unknown disease status at follow\u2010up (<jats:italic>n<\/jats:italic> = 81) were excluded from the analysis (total, <jats:italic>n<\/jats:italic> = 238).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Among patients diagnosed with breast carcinoma between 1992 and 1999, the crude overall leukemia incidence rate was 0.28%, and the acute myelogenous leukemia (AML)\/myelodysplastic syndrome (MDS) incidence rate was 0.11%. The average follow\u2010up duration was 5.46 years (minimum, 2 years). Eight incident cases of leukemia were documented (2 cases of AML, 1 case of acute lymphoblastic leukemia, 1 case of MDS\/refractory anemia with excess blasts, 2 cases of chronic myelogenous leukemia, and 2 cases of chronic lymphocytic leukemia). National age\u2010adjusted overall leukemia incidence rates for the period 1996\u20131998 predict the occurrence of 9 cases (incidence rate, 0.31%) in the current cohort of women ages 21\u201394 years. The incidence of leukemia by treatment category was as follows: no surgery\/no chemotherapy\/no radiotherapy, 2 of 154 patients (1.30%); surgery\/no chemotherapy\/radiotherapy, 4 of 1403 patients (0.29%); surgery\/chemotherapy\/no radiotherapy, 0 of 352 patients (0%); and surgery\/chemotherapy\/radiotherapy, 2 of 957 patients (0.21%).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>In contrast to findings reported from previous randomized clinical trials, the authors did not find evidence of increased posttreatment leukemia incidence in association with the use of chemotherapy, including doxorubicin\u2010based regimens. Cancer 2004. \u00a9 2004 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.20475","type":"journal-article","created":{"date-parts":[[2004,8,19]],"date-time":"2004-08-19T12:06:01Z","timestamp":1092917161000},"page":"1529-1536","source":"Crossref","is-referenced-by-count":22,"title":["Leukemia incidence following primary breast carcinoma treatment"],"prefix":"10.1002","volume":"101","author":[{"given":"Henry G.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith A.","family":"Malmgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Atwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,9,17]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_5_2_2","DOI":"10.7326\/0003-4819-105-3-360"},{"doi-asserted-by":"publisher","key":"e_1_2_5_3_2","DOI":"10.1200\/JCO.1985.3.12.1640"},{"doi-asserted-by":"publisher","key":"e_1_2_5_4_2","DOI":"10.3109\/02841869409121768"},{"doi-asserted-by":"publisher","key":"e_1_2_5_5_2","DOI":"10.1200\/JCO.2003.03.114"},{"doi-asserted-by":"publisher","key":"e_1_2_5_6_2","DOI":"10.1200\/JCO.1996.14.10.2722"},{"doi-asserted-by":"publisher","key":"e_1_2_5_7_2","DOI":"10.1016\/S0140-6736(98)03301-7"},{"key":"e_1_2_5_8_2","first-page":"1","article-title":"Adjuvant therapy for breast cancer cases","volume":"17","author":"Sledge GW","year":"2000","journal-title":"NIH Consens Statement."},{"doi-asserted-by":"publisher","key":"e_1_2_5_9_2","DOI":"10.3322\/canjclin.52.1.23"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.1998.16.7.2382","article-title":"Sixteen\u2010week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node\u2010positive, receptor negative breast cancer: an Intergroup study","volume":"16","author":"Fetting J","year":"1998","journal-title":"J Clin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_5_11_2","DOI":"10.1200\/JCO.1997.15.2.684"},{"doi-asserted-by":"publisher","key":"e_1_2_5_12_2","DOI":"10.1007\/BF01805984"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.1994.12.10.2078","article-title":"Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node\u2010positive, and estrogen receptor\u2010positive breast cancer patients: a Southwest Oncology Group study","volume":"12","author":"Rivkin SE","year":"1994","journal-title":"J Clin Oncol."},{"volume-title":"SPSS Version 11.0 [software package]","year":"2001","author":"SPSS, Inc.","key":"e_1_2_5_14_2"},{"doi-asserted-by":"publisher","key":"e_1_2_5_15_2","DOI":"10.1007\/978-1-4757-2728-9"},{"doi-asserted-by":"publisher","key":"e_1_2_5_16_2","DOI":"10.1007\/978-1-4899-4541-9"},{"key":"e_1_2_5_17_2","first-page":"2741","article-title":"Leukemia following chemotherapy for breast cancer","volume":"50","author":"Curtis RE","year":"1990","journal-title":"Cancer Res."},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1200\/JCO.1995.13.7.1557","article-title":"Leukemogenic potential of adjuvant chemotherapy for early\u2010stage breast cancer: the Eastern Cooperative Oncology Group experience","volume":"13","author":"Tallman M","year":"1995","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.1992.10.9.1444","article-title":"Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4\u2010epi\u2010doxorubicin and cisplatin or cyclophosphamide for breast cancer","volume":"10","author":"Pedersen\u2010Bjergaard J","year":"1992","journal-title":"J Clin Oncol."},{"doi-asserted-by":"publisher","key":"e_1_2_5_20_2","DOI":"10.1200\/JCO.2000.18.15.2836"},{"doi-asserted-by":"publisher","key":"e_1_2_5_21_2","DOI":"10.1056\/NEJM199206253262605"},{"doi-asserted-by":"publisher","key":"e_1_2_5_22_2","DOI":"10.1200\/JCO.1998.16.3.1008"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood.V76.6.1083.1083","article-title":"Chromosome aberrations and prognostic factors in therapy\u2010related myelodysplasia and acute nonlymphocytic leukemia","volume":"76","author":"Pederson\u2010Bjergaard J","year":"1990","journal-title":"Blood."},{"key":"e_1_2_5_24_2","first-page":"535","article-title":"All patients with the t(11;16)(q23;p13.3) that involves MLL and CBP have treatment\u2010related hematologic disorders","volume":"90","author":"Rowley J","year":"1997","journal-title":"Blood."},{"doi-asserted-by":"publisher","key":"e_1_2_5_25_2","DOI":"10.1182\/blood.V86.9.3542.bloodjournal8693542"},{"doi-asserted-by":"publisher","key":"e_1_2_5_26_2","DOI":"10.1016\/S0889-8588(05)70340-3"},{"doi-asserted-by":"publisher","key":"e_1_2_5_27_2","DOI":"10.1200\/JCO.2003.07.113"},{"doi-asserted-by":"publisher","key":"e_1_2_5_28_2","DOI":"10.1093\/annonc\/mdf289"},{"doi-asserted-by":"publisher","key":"e_1_2_5_29_2","DOI":"10.1046\/j.1365-2141.2002.03564.x"},{"key":"e_1_2_5_30_2","first-page":"1245","article-title":"Carcinogenic effects of radiotherapy for breast cancer","volume":"13","author":"Neugut AI","year":"1999","journal-title":"Oncology (Huntingt)."},{"key":"e_1_2_5_31_2","first-page":"2939","volume-title":"Cancer: principles and practice of oncology","author":"Van Leeuwen FE","year":"2001"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.20475","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.20475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:19:01Z","timestamp":1760260741000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.20475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,17]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1002\/cncr.20475"],"URL":"https:\/\/doi.org\/10.1002\/cncr.20475","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2004,9,17]]}}}